Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

Objectives To determine the incremental net health benefits of dabigatran etexilate 110 mg and 150 mg twice daily and warfarin in patients with non-valvular atrial fibrillation and to estimate the cost effectiveness of dabigatran in the United Kingdom. Design Quantitative benefit-harm and economic a...

Full description

Saved in:
Bibliographic Details
Main Authors: Pink, Joshua, Lane, Steven, Pirmohamed, Munir, Hughes, Dyfrig A
Format: Artigo
Language:Inglês
Published: BMJ Publishing Group Ltd. 2011
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC3204867/
https://ncbi.nlm.nih.gov/pubmed/22042753
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmj.d6333
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items